The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis

Objective: Non-alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation and fibrosis. There are currently no targeted therapies for NASH. We developed a liver-specific LXR inverse agonist, SR9238, which effectively reduces hepatic lipogenesis in models of obesity and hepa...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Kristine Griffett, Ryan D. Welch, Colin A. Flaveny, Grant R. Kolar, Brent A. Neuschwander-Tetri, Thomas P. Burris
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2015-04-01
Цуврал:	Molecular Metabolism
Нөхцлүүд:	NASH Fibrosis Lipogenesis LXR Inflammation
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S2212877815000228
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!